A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients.

Trial Profile

A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 28 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
    • 28 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
    • 11 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top